Resource Summary Report

Generated by RRID on Aug 26, 2026

pHR_Gal4UAS_tBFP_PGK_mCherry

RRID:Addgene_79130
Type: Plasmid

Proper Citation

RRID:Addgene_79130

Plasmid Information

URL: http://www.addgene.org/79130

Proper Citation: RRID:Addgene_79130

Insert Name: tBFP

Organism: Synthetic

Bacterial Resistance: Ampicillin

Defining Citation: PMID:26830878

Vector Backbone Description: Vector Backbone:pHR; Vector Types:Lentiviral; Bacterial Resistance:Ampicillin

Comments: Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits. Roybal KT, Rupp LJ, Morsut L, Walker WJ, McNally KA, Park JS, Lim WA. Cell. 2016 Feb 11;164(4):770-9. Epub 2016 Jan 28.

Plasmid Name: pHR_Gal4UAS_tBFP_PGK_mCherry

Record Creation Time: 20220422T222520+0000

Record Last Update: 20260815T082029+0000

Ratings and Alerts

No rating or validation information has been found for pHR_Gal4UAS_tBFP_PGK_mCherry.

No alerts have been found for pHR_Gal4UAS_tBFP_PGK_mCherry.

Data and Source Information

Source: Addgene

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Chen X, et al. (2026) Programmable macromolecule delivery via engineered trogocytosis. Nature cell biology, 28(5), 1076.

Sun S, et al. (2025) Preclinical evaluation of antitumor activity and toxicity of TROP2-specific CAR-T cells for treatment of triple-negative breast cancer. Journal for immunotherapy of cancer, 13(9).

Vogt KC, et al. (2025) Microenvironment actuated CAR T cells improve solid tumor efficacy without toxicity. Science advances, 11(4), eads3403.

Goyette MA, et al. (2024) Cancer-stromal cell interactions in breast cancer brain metastases induce glycocalyx-mediated resistance to HER2-targeting therapies. Proceedings of the National Academy of Sciences of the United States of America, 121(20), e2322688121.

Yaman S, et al. (2024) Targeted chemotherapy via HER2-based chimeric antigen receptor (CAR) engineered T-cell membrane coated polymeric nanoparticles. Bioactive materials, 34, 422.

Cortese M, et al. (2024) Preclinical efficacy of a HER2 synNotch/CEA-CAR combinatorial immunotherapy against colorectal cancer with HER2 amplification. Molecular therapy : the journal of the American Society of Gene Therapy, 32(8), 2741.

Ruffo E, et al. (2023) Post-translational covalent assembly of CAR and synNotch receptors for programmable antigen targeting. Nature communications, 14(1), 2463.

Zhu I, et al. (2022) Modular design of synthetic receptors for programmed gene regulation in cell therapies. Cell, 185(8), 1431.

Moghimi B, et al. (2021) Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma. Nature communications, 12(1), 511.

Dannenfelser R, et al. (2020) Discriminatory Power of Combinatorial Antigen Recognition in Cancer T Cell Therapies. Cell systems, 11(3), 215.

Foight GW, et al. (2019) Multi-input chemical control of protein dimerization for programming graded cellular responses. Nature biotechnology, 37(10), 1209.

Allen ME, et al. (2019) An AND-Gated Drug and Photoactivatable Cre-loxP System for Spatiotemporal Control in Cell-Based Therapeutics. ACS synthetic biology, 8(10), 2359.

Roybal KT, et al. (2016) Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors. Cell, 167(2), 419.